WO2024080194A1 - Composition et procédé d'inhibition de la croissance microbienne dans une composition - Google Patents

Composition et procédé d'inhibition de la croissance microbienne dans une composition Download PDF

Info

Publication number
WO2024080194A1
WO2024080194A1 PCT/JP2023/036137 JP2023036137W WO2024080194A1 WO 2024080194 A1 WO2024080194 A1 WO 2024080194A1 JP 2023036137 W JP2023036137 W JP 2023036137W WO 2024080194 A1 WO2024080194 A1 WO 2024080194A1
Authority
WO
WIPO (PCT)
Prior art keywords
salt
glutamic acid
composition
weight
acid
Prior art date
Application number
PCT/JP2023/036137
Other languages
English (en)
Japanese (ja)
Inventor
諒 勝部
寿栄 鈴木
Original Assignee
サントリーホールディングス株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サントリーホールディングス株式会社 filed Critical サントリーホールディングス株式会社
Publication of WO2024080194A1 publication Critical patent/WO2024080194A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/42—Preservation of non-alcoholic beverages
    • A23L2/44—Preservation of non-alcoholic beverages by adding preservatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
    • A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
    • A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
    • A23L3/3463—Organic compounds; Microorganisms; Enzymes
    • A23L3/3481—Organic compounds containing oxygen
    • A23L3/3508—Organic compounds containing oxygen containing carboxyl groups
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
    • A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
    • A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
    • A23L3/3463—Organic compounds; Microorganisms; Enzymes
    • A23L3/3526—Organic compounds containing nitrogen

Definitions

  • the present invention relates to a composition. More specifically, the present invention relates to a composition containing 3-hydroxybutyric acid or a salt thereof, and L-glutamic acid or a salt thereof. The present invention also relates to a method for inhibiting the growth of microorganisms in the composition.
  • 3-hydroxybutyric acid is a type of short-chain fatty acid, and is produced as an energy source when glucose in the body is depleted, such as during carbohydrate restriction or intense exercise. It has been reported that 3-hydroxybutyric acid has various physiological functions in addition to its function as an energy source.
  • Patent Document 1 describes an inhibitor of collagenase MMP1 and 3 production, which contains R-3-hydroxybutyric acid as an active ingredient.
  • L-glutamic acid is a type of amino acid and is known as an umami component.
  • the present invention aims to provide a composition that exhibits a microbial growth inhibitory effect.
  • the present invention aims to provide a method for inhibiting microbial growth in the composition.
  • the inventors of the present invention have conducted extensive research to solve the above problems and have found that, in a composition containing 3-hydroxybutyric acid or a salt thereof, and L-glutamic acid or a salt thereof, the proliferation of microorganisms in the composition can be effectively inhibited by setting the contents of these components within a specific range. It has not been reported that 3-hydroxybutyric acid or a salt thereof has an inhibitory effect on the proliferation of microorganisms. Similarly, it has not been reported that L-glutamic acid or a salt thereof has an inhibitory effect on the proliferation of microorganisms.
  • the inhibitory effect on the proliferation of microorganisms obtained by combining 3-hydroxybutyric acid or a salt thereof and L-glutamic acid or a salt thereof is a synergistic effect that is significantly superior to the additive effect predicted from the effects obtained when each of these is used alone.
  • a composition comprising (A) 3-hydroxybutyric acid or a salt thereof, and (B) L-glutamic acid or a salt thereof, wherein the content of the (A) 3-hydroxybutyric acid or a salt thereof is 0.08% by weight or more and 5% by weight or less, calculated as 3-hydroxybutyric acid, and the content of the (B) L-glutamic acid or a salt thereof is 0.000001% by weight or more and 0.015% by weight or less, calculated as L-glutamic acid.
  • composition according to [1] above wherein the weight ratio of the content of the (A) 3-hydroxybutyric acid or a salt thereof, calculated as 3-hydroxybutyric acid, to the content of the (B) L-glutamic acid or a salt thereof, calculated as L-glutamic acid, is 250 to 45,000.
  • the composition according to [1] or [2] above which is an oral composition.
  • [5] The composition according to any one of [1] to [4] above, which is a packaged beverage.
  • composition according to any one of [1] to [5] above which is a composition for inhibiting microbial growth.
  • a method for inhibiting the growth of microorganisms in a composition comprising adjusting the content of 3-hydroxybutyric acid or a salt thereof and the content of L-glutamic acid or a salt thereof in the composition so that the content of 3-hydroxybutyric acid or a salt thereof in the composition is 0.08% by weight or more and 5% by weight or less, calculated as 3-hydroxybutyric acid, and the content of L-glutamic acid or a salt thereof in the composition is 0.000001% by weight or more and 0.015% by weight or less, calculated as L-glutamic acid.
  • the present invention can provide a composition that exhibits a microbial growth inhibitory effect.
  • the present invention can also provide a method for inhibiting microbial growth in a composition.
  • FIG. 1 is a graph showing the antibacterial activity (%) against Staphylococcus aureus of a sample containing 0.1 wt% sodium 3-hydroxybutyrate (3HB-Na) (Test Sample 1), a sample containing 0.00001 wt% L-glutamic acid (Test Sample 2), and samples containing a combination of 3HB-Na (0.1 wt%) and L-glutamic acid (Test Samples 3 and 4).
  • 3HB-Na sodium 3-hydroxybutyrate
  • FIG. 2 is a graph showing the antibacterial activity (%) against Salmonella for a sample containing 0.1 wt % 3HB-Na (Test Sample 1), a sample containing 0.00001 wt % L-glutamic acid (Test Sample 2), and samples containing a combination of 3HB-Na (0.1 wt %) and L-glutamic acid (Test Samples 3 and 4).
  • Test Sample 1 a sample containing 0.1 wt % 3HB-Na
  • Test Sample 2 samples containing a combination of 3HB-Na (0.1 wt %) and L-glutamic acid
  • FIG. 3 is a graph showing the antibacterial activity (%) against Clostridium perfringens of a sample containing 0.5 wt % 3HB-Na (Test Sample 5), a sample containing 0.00005 wt % L-glutamic acid (Test Sample 6), and samples containing a combination of 3HB-Na (0.5 wt %) and L-glutamic acid (Test Samples 7 and 8).
  • FIG. 4 is a graph showing the antibacterial activity (%) against Staphylococcus aureus of a sample containing 5 wt % 3HB-Na (Test Sample 9), a sample containing 0.0005 wt % L-glutamic acid (Test Sample 10), and samples containing a combination of 3HB-Na (5 wt %) and L-glutamic acid (Test Samples 11 and 12).
  • FIG. 5 is a graph showing the antibacterial activity (%) against E.
  • FIG. 6 is a graph showing the antibacterial activity (%) against Listeria monocytogenes of a sample containing 5 wt% 3HB-Na (Test Sample 9), a sample containing 0.0005 wt% L-glutamic acid (Test Sample 10), a sample containing a combination of 3HB-Na (5 wt%) and L-glutamic acid (Test Samples 16 and 17), and a sample containing a combination of 3HB-Na (7.5 wt%) and L-glutamic acid (Test Samples 18 and 19).
  • the composition of the present invention contains (A) 3-hydroxybutyric acid or a salt thereof, and (B) L-glutamic acid or a salt thereof, and the content of the (A) 3-hydroxybutyric acid or a salt thereof is 0.08% by weight or more and 5% by weight or less, calculated as 3-hydroxybutyric acid, and the content of the (B) L-glutamic acid or a salt thereof is 0.000001% by weight or more and 0.015% by weight or less, calculated as L-glutamic acid.
  • contents of 3-hydroxybutyric acid or a salt thereof, and L-glutamic acid or a salt thereof in the composition are within the above ranges, the growth of microorganisms in the composition is effectively inhibited.
  • a composition in which the contents of 3-hydroxybutyric acid or a salt thereof, and L-glutamic acid or a salt thereof are within the above ranges has an excellent microbial growth inhibitory effect (antibacterial effect).
  • 3-hydroxybutyric acid or a salt thereof, and L-glutamic acid or a salt thereof are ingredients that can be used in foods, beverages, and cosmetics.
  • a composition that can exert a microbial growth inhibitory effect and can be used in foods, beverages, and the like can be provided.
  • the composition of the present invention contains 3-hydroxybutyric acid or a salt thereof.
  • 3-hydroxybutyric acid is a type of short-chain fatty acid, and is also called ⁇ -hydroxybutyric acid.
  • 3-hydroxybutyric acid may be any of the R-form (R-3-hydroxybutyric acid), the S-form (S-3-hydroxybutyric acid), and a mixture of the R-form and the S-form.
  • the 3-hydroxybutyric acid is preferably R-3-hydroxybutyric acid.
  • the salt of 3-hydroxybutyric acid is not particularly limited as long as it is a pharmacologically acceptable salt or a salt acceptable for use in foods and beverages, and examples thereof include metal salts such as sodium salt, potassium salt, magnesium salt, calcium salt, etc.; basic amino acid salts such as arginine salt, etc.
  • 3-hydroxybutyric acid or its salts are not particularly limited, and it may be a chemically synthesized product or may be produced by a fermentation method or an enzymatic method. 3-hydroxybutyric acid or its salts are commercially available, and commercially available products may also be used.
  • the content of 3-hydroxybutyric acid or its salt in the composition of the present invention is 0.08% by weight or more and 5% by weight or less in terms of 3-hydroxybutyric acid. If the content of 3-hydroxybutyric acid or its salt in the composition exceeds 5% by weight in terms of 3-hydroxybutyric acid, the microbial growth inhibitory effect of the composition may be reduced. If the content of 3-hydroxybutyric acid or its salt exceeds 5% by weight in terms of 3-hydroxybutyric acid, the unpleasant ketone odor (sweet and sour odor like rotten fruit) caused by 3-hydroxybutyric acid or its salt becomes strong.
  • the composition can exhibit an excellent microbial growth inhibitory effect and the unpleasant ketone odor caused by 3-hydroxybutyric acid or its salt is suppressed.
  • the content of 3-hydroxybutyric acid or a salt thereof in the composition is preferably 0.1% by weight or more, more preferably 0.4% by weight or more, even more preferably 0.5% by weight or more, and is preferably 4.5% by weight or less, more preferably 4.2% by weight or less, in terms of 3-hydroxybutyric acid.
  • the content of 3-hydroxybutyric acid or a salt thereof in the composition is preferably 0.08 to 4.5% by weight, more preferably 0.1 to 4.5% by weight, even more preferably 0.4 to 4.5% by weight, particularly preferably 0.5 to 4.2% by weight, in terms of 3-hydroxybutyric acid.
  • the amount converted into 3-hydroxybutyric acid or similar expressions refer to the amount of 3-hydroxybutyric acid, and in the case of a salt of 3-hydroxybutyric acid, the value obtained by multiplying the number of moles of the salt by the molecular weight of 3-hydroxybutyric acid.
  • the content of 3-hydroxybutyric acid or a salt thereof can be measured by high performance liquid chromatography (HPLC).
  • the composition of the present invention contains L-glutamic acid or a salt thereof.
  • the salt of L-glutamic acid is not particularly limited as long as it is a pharmacologically acceptable salt or a salt acceptable for use in foods and beverages, and examples thereof include metal salts such as sodium salt, potassium salt, magnesium salt, calcium salt, etc.; basic amino acid salts such as arginine salt, etc.
  • L-glutamic acid or its salts are not particularly limited, and it may be a chemically synthesized product or may be produced by a fermentation method or an enzymatic method.
  • L-glutamic acid or its salts may be derived from natural products, or may be extracted and purified from natural products.
  • L-glutamic acid or its salts are commercially available, and commercially available products may also be used.
  • the content of L-glutamic acid or a salt thereof in the composition of the present invention is 0.000001% by weight or more and 0.015% by weight or less in terms of L-glutamic acid. If the content of L-glutamic acid or a salt thereof in the composition is 0.015% by weight or less in terms of L-glutamic acid, there is an advantage that, for example, when the composition is used as an oral composition such as a food or drink, the umami taste caused by L-glutamic acid or a salt thereof is unlikely to become excessive.
  • the content of L-glutamic acid or a salt thereof in the composition is preferably 0.00001% by weight or more, more preferably 0.0001% by weight or more, and also preferably 0.01% by weight or less, more preferably 0.001% by weight or less, in terms of L-glutamic acid.
  • the content of L-glutamic acid or a salt thereof in the composition is preferably 0.00001 to 0.01% by weight, more preferably 0.0001 to 0.001% by weight, in terms of L-glutamic acid.
  • the amount in terms of L-glutamic acid or expressions similar thereto means the amount of L-glutamic acid in the case of L-glutamic acid, and in the case of a salt of L-glutamic acid, the value obtained by multiplying the number of moles of the salt by the molecular weight of L-glutamic acid.
  • the content of L-glutamic acid or a salt thereof can be measured by high performance liquid chromatography (HPLC).
  • the weight ratio of the content of (A) 3-hydroxybutyric acid or a salt thereof, calculated as 3-hydroxybutyric acid, to the content of (B) L-glutamic acid or a salt thereof, calculated as L-glutamic acid is preferably 250 or more and preferably 45,000 or less. This is because a higher microbial growth inhibitory effect can be obtained.
  • the weight ratio ((A) calculated as 3-hydroxybutyric acid/(B) calculated as L-glutamic acid) is more preferably 270 or more, even more preferably 500 or more, and more preferably 42,000 or less, even more preferably 10,000 or less.
  • the weight ratio of the content of (A) 3-hydroxybutyric acid or a salt thereof calculated as 3-hydroxybutyric acid to the content of (B) L-glutamic acid or a salt thereof calculated as L-glutamic acid is preferably 250 to 45,000, more preferably 270 to 42,000, even more preferably 500 to 10,000.
  • the composition of the present invention preferably contains 3-hydroxybutyric acid or a salt thereof and L-glutamic acid or a salt thereof in the above weight ratio.
  • the composition of the present invention can be used to inhibit the growth of microorganisms.
  • the composition of the present invention can be preferably used as a composition for inhibiting the growth of microorganisms.
  • the composition for inhibiting the growth of microorganisms can be used in applications where a microbial growth inhibitory effect should be exerted.
  • the composition of the present invention can be used to inhibit the growth of microorganisms in the composition itself.
  • the composition of the present invention is useful as a composition in which the growth of microorganisms is inhibited.
  • microorganisms include not only bacteria but also fungi (mushrooms, molds, yeasts, etc.), viruses, microalgae, etc., but in this specification, microorganisms refer to bacteria.
  • the microorganism may be either a gram-positive bacterium or a gram-negative bacterium.
  • gram-positive bacteria include Staphylococcus aureus, Listeria monocytogenes, Clostridium perfringens, etc.
  • gram-negative bacteria include Salmonella enterica subsp. enterica, Escherichia coli, etc.
  • Microorganisms such as Staphylococcus aureus, Salmonella, Clostridium perfringens, Listeria, and Escherichia coli are causative bacteria of food poisoning.
  • the microorganism in the present invention is preferably at least one selected from the group consisting of Staphylococcus aureus, Salmonella enterica subsp. enterica, Clostridium perfringens, Escherichia coli, and Listeria monocytogenes. These microorganisms are causative bacteria of food poisoning.
  • the composition of the present invention can exert an excellent growth inhibitory effect against the above microorganisms. Among them, as the microorganism, Staphylococcus aureus and Escherichia coli are more preferable, and Escherichia coli is even more preferable.
  • the composition of the present invention is preferably used for inhibiting the growth of at least one microorganism selected from the group consisting of Staphylococcus aureus, Salmonella enterica subsp. enterica, Clostridium perfringens, Escherichia coli, and Listeria monocytogenes.
  • the composition of the present invention is more preferably used to inhibit the growth of Staphylococcus aureus and/or Escherichia coli, and even more preferably used to inhibit the growth of Escherichia coli.
  • the composition of the present invention may be either an oral composition or a parenteral composition.
  • the composition of the present invention is preferably an oral composition.
  • the composition of the present invention is useful as an oral composition in which the proliferation of microorganisms is inhibited.
  • oral compositions include food and drink, oral medicines, quasi-drugs, feed, etc., and are preferably food and drink or oral medicines, and more preferably food and drink.
  • the composition of the present invention can be used, for example, as a skin topical agent (skin topical composition). Skin topical agents include cosmetics, medicines, quasi-drugs, etc., and are preferably cosmetics.
  • the composition of the present invention may be a food or drink, a cosmetic, a medicine, a quasi-drug, a feed, or the like, or may be a material or preparation to be mixed with these and used therein.
  • the composition of the present invention may contain any additives and any components in addition to 3-hydroxybutyric acid or a salt thereof, and L-glutamic acid or a salt thereof, so long as the effects of the present invention are not impaired. These additives and components may be selected depending on the form of the composition, and those that are generally usable for foods and beverages, cosmetics, medicines, quasi-drugs, feeds, etc. may be used.
  • the composition of the present invention may contain a physiologically active component or a pharmacologically active component other than 3-hydroxybutyric acid or a salt thereof, and L-glutamic acid or a salt thereof.
  • the production method thereof is not particularly limited, and it may be produced by a general method.
  • the form of the composition of the present invention is not particularly limited, and may be a solid (powder, granules, tablet, etc.), liquid, paste, etc.
  • the composition of the present invention when the composition of the present invention is made into a food or drink, the composition may contain, in addition to 3-hydroxybutyric acid or a salt thereof, and L-glutamic acid or a salt thereof, ingredients that can be used in food or drink (e.g., food ingredients, food additives, etc.).
  • ingredients that can be used in food or drink e.g., food ingredients, food additives, etc.
  • food or drink There are no particular limitations on the food or drink, and examples include general food and drink, health foods, health drinks, functional foods, foods for specified health uses, dietary supplements, and foods and drink for medical patients.
  • the above-mentioned health foods, functional foods, foods for specified health uses, dietary supplements, and foods and drink for medical patients can be in various formulation forms, such as fine granules, tablets, granules, powders, capsules, chewable tablets, syrups, liquids, and liquid diets.
  • the composition of the present invention can be prepared into various dosage forms of a drug or quasi-drug by blending 3-hydroxybutyric acid or a salt thereof, and L-glutamic acid or a salt thereof with a pharmacologically acceptable carrier, additives added as necessary, and the like.
  • a pharmacologically acceptable carrier such as any pharmacologically acceptable carriers that can be used for drugs or quasi-drugs, and examples thereof include one or more of excipients, binders, disintegrants, lubricants, antioxidants, colorants, and the like.
  • dosage forms of drugs or quasi-drugs include oral or parenteral administration forms, with oral administration forms being preferred.
  • the composition of the present invention is used as a drug or quasi-drug, it is preferred to use an oral drug or an oral quasi-drug.
  • dosage forms for oral administration include liquids, tablets, powders, fine granules, granules, sugar-coated tablets, capsules, suspensions, emulsions, chewables, and the like.
  • dosage forms for parenteral administration include external preparations, injections, drip infusions, and the like.
  • the pharmaceutical or quasi-drug is preferably a skin external preparation.
  • the dosage form of the skin external preparation is not particularly limited, and may be any form such as a solution, emulsion, cream, gel, powder, aerosol, mist, capsule, and sheet.
  • the pharmaceutical may be a drug for non-human animals.
  • composition of the present invention When the composition of the present invention is used as a cosmetic product, various types of cosmetic products can be produced by blending 3-hydroxybutyric acid or a salt thereof and L-glutamic acid or a salt thereof with ingredients that can be used in cosmetics (e.g., carriers, additives, etc. that are acceptable for cosmetics).
  • the product form of the cosmetic product is not particularly limited, and examples include skin care cosmetics such as lotion, beauty essence, pack, milky lotion, cream, and sunscreen.
  • the composition of the present invention When the composition of the present invention is used as a feed, the composition may contain, in addition to 3-hydroxybutyric acid or a salt thereof, and L-glutamic acid or a salt thereof, other components that can be used in feed. Feed also includes feed additives. Examples of feed include livestock feed for cows, pigs, chickens, sheep, horses, etc.; small animal feed for rabbits, rats, mice, etc.; and pet food for dogs, cats, small birds, etc.
  • the composition of the present invention can effectively inhibit the growth of microorganisms even in a liquid state.
  • the composition of the present invention is preferably a liquid composition, more preferably a beverage.
  • the composition of the present invention can be provided as a beverage.
  • the beverage is not particularly limited, and examples thereof include non-alcoholic beverages and alcoholic beverages, with non-alcoholic beverages being preferred.
  • the non-alcoholic beverage refers to a beverage having an ethanol concentration of 1.2 v/v% or less, preferably an ethanol concentration of 1.0 v/v% or less, more preferably an ethanol concentration of 0.5 v/v% or less.
  • non-alcoholic beverages include tea beverages, coffee beverages, non-alcoholic beer-flavored beverages, carbonated beverages, functional beverages, fruit and vegetable beverages, dairy beverages, soy milk beverages, and flavored waters.
  • tea beverages black tea beverages and unsweetened tea beverages are preferable.
  • unsweetened tea beverages include green tea beverages, oolong tea beverages, barley tea beverages, brown rice tea beverages, pearl barley tea beverages, and unsweetened black tea beverages.
  • Coffee beverages include packaged coffee, liquid coffee, and the like.
  • non-alcoholic beer-flavored beverage refers to a carbonated beverage that has a beer-like flavor and is a non-fermented, non-alcoholic beverage that contains substantially no alcohol.
  • non-alcoholic beer-flavored beverage does not exclude beverages that contain trace amounts of alcohol that are undetectable.
  • Carbonated drinks include cola-flavored drinks, clear carbonated drinks, ginger ale, fruit juice carbonated drinks, dairy carbonated drinks, sugar-free carbonated drinks, and the like.
  • Examples of functional drinks include sports drinks, energy drinks, health support drinks, pouch jelly drinks, etc.
  • Examples of fruit and vegetable drinks include 100% fruit drinks, drinks containing fruit, soft drinks with low fruit juice content, fruit drinks containing fruit particles, and pulp drinks.
  • the beverage can be packaged in a container.
  • the shape of the container is not particularly limited, and examples include bottles, cans, PET bottles, paper cartons, aluminum pouches, vinyl pouches, and the like.
  • the beverage (liquid for internal use) can be filled into a sealed container as described above to produce a packaged beverage, etc.
  • the embodiment in which the composition of the present invention is a packaged beverage is one of the preferred embodiments of the present invention.
  • the subject to which the composition of the present invention is ingested or administered (which may also be referred to as the administration subject) is not particularly limited.
  • the subject is a human or a non-human mammal, and more preferably, the subject is a human.
  • the intake amount (dosage) of the composition of the present invention is not particularly limited, but for example, for humans (adults), the intake amount of 3-hydroxybutyric acid or a salt thereof per day, calculated as 3-hydroxybutyric acid, is preferably 100 to 100,000 mg, more preferably 300 to 5,000 mg, and even more preferably 500 to 3,500 mg.
  • the above intake amount is preferably per 60 kg of body weight per day.
  • the combination of 3-hydroxybutyric acid or a salt thereof and L-glutamic acid or a salt thereof can be used as an active ingredient for inhibiting the growth of microorganisms.
  • the composition of the present invention may contain 3-hydroxybutyric acid or a salt thereof, and L-glutamic acid or a salt thereof as active ingredients.
  • the composition of the present invention can also be used, for example, for inhibiting the growth of microorganisms in an application target.
  • the composition of the present invention can be added to an oral composition to inhibit the growth of microorganisms in the oral composition, for example.
  • the present invention also encompasses a method for inhibiting the growth of microorganisms in a composition, which comprises adjusting the content of 3-hydroxybutyric acid or a salt thereof and the content of L-glutamic acid or a salt thereof in the composition so that the content of 3-hydroxybutyric acid or a salt thereof in the composition is from 0.08% by weight to 5% by weight, calculated as 3-hydroxybutyric acid, and the content of L-glutamic acid or a salt thereof is from 0.000001% by weight to 0.015% by weight, calculated as L-glutamic acid.
  • the preferred embodiments of 3-hydroxybutyric acid or a salt thereof and L-glutamic acid or a salt thereof are the same as those of the composition of the present invention described above.
  • the microorganism and its preferred embodiment are the same as those described above, and is preferably at least one selected from the group consisting of Staphylococcus aureus, Salmonella enterica subsp. enterica, Clostridium perfringens, Escherichia coli, and Listeria monocytogenes, and more preferably Staphylococcus aureus and/or Escherichia coli.
  • Escherichia coli is even more preferred.
  • the weight ratio of the content of (A) 3-hydroxybutyric acid or a salt thereof in terms of 3-hydroxybutyric acid to the content of (B) L-glutamic acid or a salt thereof in terms of L-glutamic acid in the composition is preferably 250 to 45,000, more preferably 270 to 42,000, and even more preferably 500 to 10,000.
  • the method for adjusting the content of 3-hydroxybutyric acid or a salt thereof and the content of L-glutamic acid or a salt thereof in the composition is not particularly limited, and for example, 3-hydroxybutyric acid or a salt thereof, and L-glutamic acid or a salt thereof may be added to the composition. In the present invention, it is sufficient that the content of 3-hydroxybutyric acid or a salt thereof, and L-glutamic acid or a salt thereof in the composition finally reaches the above-mentioned contents.
  • 3-hydroxybutyric acid or a salt thereof, and L-glutamic acid or a salt thereof may be added separately to the composition, or a composition containing them may be added to the composition in which the growth of microorganisms is to be inhibited.
  • the composition to be treated for inhibiting microbial growth is preferably an oral composition.
  • the method of the present invention is preferably a method for inhibiting microbial growth in an oral composition.
  • the composition to be treated is more preferably a liquid oral composition, and even more preferably a beverage.
  • the present invention also includes the use of 3-hydroxybutyric acid or a salt thereof, and L-glutamic acid or a salt thereof to inhibit the growth of microorganisms in a composition.
  • 3-hydroxybutyric acid or a salt thereof, and L-glutamic acid or a salt thereof so that the content of 3-hydroxybutyric acid or a salt thereof in the composition is 0.08% by weight or more and 5% by weight or less, calculated as 3-hydroxybutyric acid, and the content of L-glutamic acid or a salt thereof is 0.000001% by weight or more and 0.015% by weight or less, calculated as L-glutamic acid.
  • a numerical range expressed by a lower limit and an upper limit includes the lower limit and the upper limit.
  • a range expressed by "1 to 2" means 1 to 2, including 1 and 2.
  • the upper and lower limits may be in any combination.
  • 3-hydroxybutyric acid (hereinafter, referred to as 3HB) was mixed with water to prepare an aqueous solution containing 3HB at the concentration (content) shown in Table 1, and three well-trained panelists performed a sensory evaluation.
  • the 3HB concentration was shown in weight % and ppm. ppm is weight ppm, and 1 weight ppm represents 10-4 weight %.
  • the evaluation criteria were based on the strength of the ketone odor of the 3HB-containing aqueous solution (at room temperature), and the evaluation was performed in increments of 1 point (5 levels) using the following criteria (1 to 5 points), and then the average score of the panelists was calculated.
  • R-3-hydroxybutyric acid D-3-hydroxybutyric acid
  • Osaka Gas Co., Ltd. was used as 3HB.
  • the evaluation results are shown in Table 1. At concentrations of 5% by weight (50,000 ppm) or less, the panelists' average score was below 3 points, indicating that the drink could be consumed without worrying too much about the ketone odor. On the other hand, at concentrations of 7.5% by weight (75,000 ppm) or more, all panelists detected the ketone odor and the average score exceeded 4 points, indicating that the unpleasant ketone odor was felt when drinking or using the drink.
  • Example 1 The antibacterial (microbial growth inhibitory) effects of 3HB and L-glutamic acid (hereinafter sometimes simply referred to as glutamic acid) were investigated.
  • sodium 3HB was used as D-3-hydroxybutyrate (Sigma-Aldrich) (hereinafter referred to as 3HB-Na).
  • the test bacteria used were Staphylococcus aureus (NBRC 12732), Salmonella enterica subsp. enterica NBRC 100797, Clostridium perfringens (JCM 1290), Escherichia coli (NBRC 3972), and Listeria monocytogenes (JCM 7671).
  • Staphylococcus aureus, Salmonella enterica, and Escherichia coli were inoculated onto normal agar medium and cultured at 30 to 35° C. for 24 hours.
  • Clostridium perfringens was inoculated onto Columbia agar medium and cultured anaerobically at 37° C. for 24 hours.
  • Listeria monocytogenes was inoculated onto Listeria selective medium and cultured at 30 to 35° C. for 24 hours. After culture, saline was used to adjust the bacterial count to 10 8 CFU/mL, and this was used as the test bacterial solution.
  • test sample 1 3HB-Na concentration (content) 0.1% by weight (1000 ppm)
  • Phosphate buffered saline and glutamic acid were mixed to prepare test sample 2 (glutamic acid concentration: 0.00001% by weight (0.1 ppm)
  • test sample 3 3HB-Na concentration 0.1% by weight (1000 ppm), glutamic acid concentration 0.000002% by weight (0.02 ppm)).
  • test sample 4 Phosphate buffered saline, 3HB-Na and glutamic acid were mixed to prepare test sample 4 (3HB-Na concentration 0.1% by weight (1000 ppm), glutamic acid concentration 0.00001% by weight (0.1 ppm)).
  • Phosphate buffered saline and 3HB-Na were mixed to prepare test sample 5 (3HB-Na concentration: 0.5% by weight (5000 ppm)).
  • test sample 6 Glutamic acid concentration: 0.00005% by weight (0.5 ppm)).
  • test sample 7 Phosphate buffered saline, 3HB-Na and glutamic acid were mixed to prepare test sample 7 (3HB-Na concentration: 0.5% by weight (5000 ppm), glutamic acid concentration: 0.00001% by weight (0.1 ppm)).
  • Phosphate buffered saline, 3HB-Na and glutamic acid were mixed to prepare test sample 8 (3HB-Na concentration: 0.5% by weight (5000 ppm), glutamic acid concentration: 0.00005% by weight (0.5 ppm)).
  • test sample 9 3HB-Na concentration: 5% by weight (50,000 ppm)).
  • Phosphate buffered saline and glutamic acid were mixed to prepare test sample 10 (glutamic acid concentration: 0.0005% by weight (5 ppm)).
  • test sample 11 3HB-Na concentration 5% by weight (50,000 ppm), glutamic acid concentration 0.0001% by weight (1 ppm)
  • test sample 12 3HB-Na concentration 5% by weight (50,000 ppm), glutamic acid concentration 0.0005% by weight (5 ppm)
  • test sample 13 Phosphate buffered saline and glutamic acid were mixed to prepare test sample 13 (glutamic acid concentration: 0.015% by weight (150 ppm)).
  • test sample 14 Phosphate buffered saline, 3HB-Na and glutamic acid were mixed to prepare test sample 14 (3HB-Na concentration 5% by weight (50,000 ppm), glutamic acid concentration 0.005% by weight (50 ppm)).
  • Phosphate buffered saline, 3HB-Na and glutamic acid were mixed to prepare test sample 15 (3HB-Na concentration 5% by weight (50,000 ppm), glutamic acid concentration 0.015% by weight (150 ppm)).
  • test sample 16 3HB-Na concentration 5% by weight (50,000 ppm), glutamic acid concentration 0.0001% by weight (1 ppm)).
  • test sample 17 3HB-Na concentration 5% by weight (50,000 ppm), glutamic acid concentration 0.0005% by weight (5 ppm)).
  • Phosphate buffered saline, 3HB-Na and glutamic acid were mixed to prepare test sample 18 (3HB-Na concentration 7.5% by weight (75,000 ppm), glutamic acid concentration 0.00015% by weight (1.5 ppm)).
  • test sample 19 3HB-Na concentration 7.5% by weight (75,000 ppm), glutamic acid concentration 0.00075% by weight (7.5 ppm)).
  • Phosphate buffered saline served as a control, and all test samples were adjusted to a pH of approximately 7.6.
  • Table 2 shows the concentrations (weight %) of 3HB-Na and glutamic acid (Glu) in the test samples.
  • Table 3 shows the concentrations of each component in the test samples shown in Table 2 in ppm.
  • the "(A) in 3HB equivalent” shows the concentration of 3HB-Na in 3HB equivalent.
  • Tables 2 and 3 show the weight ratio (weight ratio (3HB/Glu)) of the concentration of 3HB-Na in 3HB equivalent (A) to the concentration of glutamic acid (B).
  • test bacteria liquid 0.02 mL of the test bacteria liquid was inoculated into 2 mL of the test sample and allowed to stand at room temperature.
  • Antibacterial activity 100 - 100 x (number of viable bacteria in test sample) / (number of viable bacteria in control)
  • the test samples were diluted one hour after inoculation and cultured using the above method.
  • the results are shown in Figure 1.
  • the test samples were diluted 24 hours after inoculation and cultured using the above method.
  • the results are shown in Figure 4.
  • FIG. 1 is a graph showing the antibacterial activity (%) of 0.1% by weight (1000 ppm) 3HB-Na (Test Sample 1), 0.00001% by weight (0.1 ppm) L-glutamic acid (Test Sample 2), and a combination of 0.1% by weight 3HB-Na and L-glutamic acid (Test Samples 3 and 4) against Staphylococcus aureus.
  • 0.1% by weight 3HB-Na and 0.00001% by weight L-glutamic acid weakly inhibited the growth of Staphylococcus aureus (Test Samples 1 and 2).
  • the antibacterial effect against Staphylococcus aureus obtained by the combination of 0.1% by weight 3HB-Na and L-glutamic acid was a synergistic effect that was significantly superior to the additive effect predicted from the effect obtained by using each component alone (Test Samples 3 and 4).
  • 0.1% by weight of 3HB-Na is equivalent to 0.08256% by weight (825.6 ppm) of 3HB. It was found that the combined use of 3HB or a salt thereof and L-glutamic acid or a salt thereof provides an excellent antibacterial effect against microorganisms, i.e., an excellent effect of inhibiting the growth of microorganisms.
  • Figure 2 is a graph showing the antibacterial activity (%) of 0.1% by weight 3HB-Na (test sample 1), 0.00001% by weight L-glutamic acid (test sample 2), and a combination of 0.1% by weight 3HB-Na and L-glutamic acid (test samples 3 and 4) against Salmonella.
  • 0.1% by weight 3HB-Na and 0.00001% by weight L-glutamic acid alone did not show any antibacterial effect against Salmonella.
  • the combination of 0.1% by weight 3HB-Na and L-glutamic acid demonstrated a new antibacterial effect against Salmonella. It was found that the combined use of 3HB or a salt thereof and L-glutamic acid or a salt thereof provides an excellent antibacterial effect against microorganisms, i.e., an excellent effect of inhibiting the growth of microorganisms.
  • Figure 3 is a graph showing the antibacterial activity (%) of 0.5 wt% (5000 ppm) 3HB-Na (Test Sample 5), 0.00005 wt% (0.5 ppm) L-glutamic acid (Test Sample 6), and a combination of 0.5 wt% 3HB-Na and L-glutamic acid (Test Samples 7 and 8) against Clostridium perfringens.
  • 0.00005 wt% L-glutamic acid alone had no antibacterial effect against Clostridium perfringens (Test Sample 6).
  • Figure 4 is a graph showing the antibacterial activity (%) of 5 wt% (50,000 ppm) 3HB-Na (Test Sample 9), 0.0005 wt% (5 ppm) L-glutamic acid (Test Sample 10), and a combination of 5 wt% 3HB-Na and L-glutamic acid (Test Samples 11 and 12) against Staphylococcus aureus. 0.0005 wt% L-glutamic acid alone had no antibacterial effect against Staphylococcus aureus (Test Sample 10).
  • Figure 5 is a graph showing the antibacterial activity (%) of 5 wt% 3HB-Na (Test Sample 9), 0.015 wt% (150 ppm) L-glutamic acid (Test Sample 13), and a combination of 5 wt% 3HB-Na and L-glutamic acid (Test Samples 14 and 15) against E. coli.
  • 0.015 wt% L-glutamic acid alone had no antibacterial effect against E. coli (Test Sample 13).
  • 5 wt% 3HB-Na inhibited the growth of E. coli when used alone (Test Sample 9), but the antibacterial effect against E.
  • coli obtained by the combination of 3HB-Na and L-glutamic acid was a synergistic effect that was significantly superior to the additive effect predicted from the effect obtained by using each component alone (Test Samples 14 and 15). It was found that the combined use of 3HB-Na or a salt thereof and L-glutamic acid or a salt thereof provides an excellent antibacterial effect against microorganisms, i.e., an excellent effect of inhibiting the growth of microorganisms.
  • Figure 6 is a graph showing the antibacterial activity (%) of 5 wt% 3HB-Na (test sample 9), 0.0005 wt% L-glutamic acid (test sample 10), a combination of 5 wt% 3HB-Na and L-glutamic acid (test samples 16 and 17), and a combination of 7.5 wt% (75,000 ppm) 3HB-Na and L-glutamic acid (test samples 18 and 19) against Listeria.
  • 5 wt% 3HB-Na and 0.0005 wt% L-glutamic acid alone did not show any antibacterial effect against Listeria (test samples 9 and 10).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La présente invention aborde le problème de la fourniture d'une composition exerçant un effet inhibiteur de croissance microbienne et un procédé d'inhibition de la croissance microbienne dans une composition. La présente invention concerne une composition contenant (A) de l'acide 3-hydroxybutyrique ou un sel de celui-ci et (B) de l'acide L-glutamique ou un sel de celui-ci, la teneur en acide 3-hydroxybutyrique (A) ou un sel de celui-ci étant comprise entre 0,08 et 5 % en poids inclus en termes d'acide 3-hydroxybutyrique, et la teneur en acide L-glutamique (B) ou en un sel de celui-ci étant comprise entre 0,000001 et 0,015 % en poids inclus en termes d'acide L-glutamique.
PCT/JP2023/036137 2022-10-12 2023-10-04 Composition et procédé d'inhibition de la croissance microbienne dans une composition WO2024080194A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022-164105 2022-10-12
JP2022164105 2022-10-12

Publications (1)

Publication Number Publication Date
WO2024080194A1 true WO2024080194A1 (fr) 2024-04-18

Family

ID=90669170

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2023/036137 WO2024080194A1 (fr) 2022-10-12 2023-10-04 Composition et procédé d'inhibition de la croissance microbienne dans une composition

Country Status (2)

Country Link
TW (1) TW202423305A (fr)
WO (1) WO2024080194A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58216682A (ja) * 1982-06-10 1983-12-16 Isamu Miyazaki 経口摂取物用添加組成物
WO2021132539A1 (fr) * 2019-12-27 2021-07-01 株式会社 ブルボン Régulateur de croissance cellulaire
WO2023162808A1 (fr) * 2022-02-25 2023-08-31 サントリーホールディングス株式会社 Agent et procédé d'inhibition de prolifération de bactéries acidophiles résistantes à la chaleur

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58216682A (ja) * 1982-06-10 1983-12-16 Isamu Miyazaki 経口摂取物用添加組成物
WO2021132539A1 (fr) * 2019-12-27 2021-07-01 株式会社 ブルボン Régulateur de croissance cellulaire
WO2023162808A1 (fr) * 2022-02-25 2023-08-31 サントリーホールディングス株式会社 Agent et procédé d'inhibition de prolifération de bactéries acidophiles résistantes à la chaleur

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MA LINLIN, ZHANG ZIHENG, LI JUN, YANG XINGXING, FEI BIN, LEUNG POLLY H. M., TAO XIAOMING: "A New Antimicrobial Agent: Poly (3‐hydroxybutyric acid) Oligomer", MACROMOLECULAR BIOSCIENCE, WILEY-VCH VERLAG GMBH, DE, vol. 19, no. 5, 1 May 2019 (2019-05-01), DE , pages 1800432, XP093116442, ISSN: 1616-5187, DOI: 10.1002/mabi.201800432 *

Also Published As

Publication number Publication date
TW202423305A (zh) 2024-06-16

Similar Documents

Publication Publication Date Title
AU2007347990B2 (en) Oral disinfectant and food additive comprising the disinfectant
JP2021119787A (ja) ペプチド組成物およびその製造方法
JP5507802B2 (ja) 筋肉老化抑制剤
CA2499665A1 (fr) Utilisation de glucides ou de compositions en contenant pour le traitement ou la prevention des affections causees par une fermentation desequilibree dans le colon
Pugazhenthi et al. Preparation of functional Shrikhand with pomegranate fruit peel extracts
JP2005515962A (ja) 糖質改変薬剤およびこの改変薬剤を含む飲料
JP4201779B2 (ja) 新規な没食子酸共役リノール酸脂肪エステル、その製造方法及びそれを含む組成物
WO2024080194A1 (fr) Composition et procédé d'inhibition de la croissance microbienne dans une composition
WO2023213550A1 (fr) Procédé de prévention et/ou d'inhibition de l'excroissance, de la sporulation, de la germination ou de la formation de toxines de clostridium
JP2023096136A (ja) 労働パフォーマンスの向上用組成物
KR20100037310A (ko) 김치 유산균을 이용한 액상 건강보조식품의 제조방법
KR102158134B1 (ko) 오미자 추출물을 유효성분으로 함유하는 항균용 조성물
KR101776511B1 (ko) 락토바실러스 플란타룸으로 발효시킨 향나무 열매 배양액의 리스테리아 항균조성물
KR20150133351A (ko) 플라보놀계 화합물 및 항생물질을 유효성분으로 포함하는 항균 조성물
KR20090130136A (ko) 헬리코박터ㆍ파일로리 제균제
JP2005343823A (ja) 抗菌剤組成物
KR102011721B1 (ko) 포도상구균의 생육을 억제하는 한천 유래 올리고당의 용도
KR20100020123A (ko) 복합 김치유산균으로 발효한 콩 발효물을 유효성분으로 함유하는 식중독 예방 및 치료용 조성물
US20030017219A1 (en) Carbohydrate modifying agent and drinks containing the modifying agent
JP2019142976A (ja) 免疫賦活剤
KR20190014873A (ko) 참가시나무 열매 및 바나바 잎의 혼합 추출물을 유효성분으로 함유하는 항균용 조성물
JP6829487B2 (ja) 抗疲労剤
WO2023234338A1 (fr) Composition, composition pour inhiber la croissance microbienne, et procédé pour inhiber la croissance microbienne dans une composition orale
JP2017171610A (ja) 口臭抑制用組成物
KR20150125636A (ko) 쥐티푸스균으로 유발되는 식중독 또는 급성위장염의 치료 및 예방용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23877199

Country of ref document: EP

Kind code of ref document: A1